Cambridge, MA & Columbia, MD — November 26, 2024 — Trifermed, founded in 2002, a strategic partnership company empowering health innovators to transform ideas into impactful solutions, and CSSi LifeSciences, a leading U.S.- based regulatory consulting and commercialization services provider, are pleased to announce their strategic partnership. Together, the two firms will offer comprehensive support for biopharma, MedTech, and digital health companies worldwide seeking to establish a successful presence in the U.S. market.
Strengthening Global Partnerships to Drive U.S. Market Success
Since 2016, Trifermed has been active in the U.S. market, solidifying its North American presence in 2023 with a fully owned subsidiary in Cambridge, MA. This step marks a pivotal milestone, led by Prof. Dr. Sergi Trilla, following years of involvement in U.S.-based biotech initiatives, including his executive role at Veru. Globally, Trifermed’s track record includes the orchestration of over 200 strategic partnerships, underscoring its commitment to advancing health innovation across Pharma, Biotech, MedTech, and digital health. With additional bases in Barcelona and a representative office in Mexico City, Trifermed supports clients in addressing complex strategic challenges and forming high-value partnerships. CSSi LifeSciences, a trusted partner in FDA submissions and commercialization, brings decades of regulatory expertise, with successful approvals across a diverse range of therapeutics, biologics, and medical devices. By aligning CSSi LifeSciences in-depth regulatory knowledge with Trifermed’s strategic partnership capabilities, this collaboration will facilitate a structured, expedited approach to U.S. market access for healthcare innovators around the globe.
A Tailored Pathway to U.S. Market Entry
The combined strengths of CSSi LifeSciences and Trifermed enable a fully integrated support model for U.S. market entry. CSSi LifeSciences provides rigorous regulatory and clinical development support, mitigating risks while optimizing timelines. By working with Trifermed, healthcare companies gain a Sunday, 12 December, 2023 strategic ally for developing partnerships, refining business models, and maximizing growth potential. The collaboration will empower clients to navigate the U.S. healthcare ecosystem with both strategic foresight and regulatory precision.
“Our partnership with CSSi LifeSciences strengthens our shared vision of simplifying market entry for global healthcare innovators,” said Prof. Sergi X. Trilla, President & CEO of Trifermed. “By combining CSSi LifeSciences regulatory expertise with Trifermed’s experience in strategic partnership-building, we offer companies a pathway to launch their innovations in the U.S. market with confidence and agility.”
Engaging with Industry Leaders at J.P. Morgan Healthcare Conference 2025
CSSi LifeSciences has invited Trifermed to participate in their exclusive event at the J.P. Morgan Healthcare Conference in San Francisco, January 2025. During the event, Trifermed will be fully immersed in CSSi LifeSciences program, meeting with companies seeking strategic partnerships for U.S. market expansion as well as international growth. This collaboration underscores CSSi LifeSciences dedication to providing a platform for global innovators to connect and explore key insights into successful market entry.
“CSSi LifeSciences is pleased to welcome Trifermed to our J.P. Morgan event, where we’re committed to helping innovators succeed in the competitive U.S. market,” stated Jim Sergi, President of CSSi LifeSciences. “Our alliance with Trifermed amplifies our ability to provide meaningful pathways for growth, connecting clients to the right partners, resources, and strategic insights for long-term success.”
About CSSi LifeSciences
CSSi LifeSciences is a global regulatory consulting firm specializing in regulatory and commercialization services for drugs and medical devices. Known for its extensive FDA experience, CSSi LifeSciences guides clients through complex regulatory landscapes with a commitment to reducing time and costs-to-market and enhancing commercial success.
Contact us:
Jim Sergi | President & Founder info@qnovals.com QNovaLifeSciences.com 6751 Columbia Gateway Drive, Suite 300, Columbia, MD 21046 www.linkedin.com/in/jim-sergi/
About Trifermed
Founded in 2002, Trifermed is the strategic partner of choice for health innovators seeking to transform ideas into global impact. Specializing in biopharma, MedTech, and digital health, Trifermed has facilitated over 200 partnerships worldwide, connecting innovators, investors, and deployers to create meaningful change in healthcare. Operating from Barcelona and Cambridge, MA, Trifermed collaborates with clients to navigate challenges, refine strategies, and build ecosystems that drive sustainable growth and societal impact.
Contact us:
Prof. Sergi X. Trilla, MD, MBA | President & CEO strilla@trifermed.com www.trifermed.com 165 Main Street, Unit 1115, Cambridge, MA 02142, USA www.linkedin.com/in/profdrsergitrilla/